Aptevo Therapeutics Inc - Asset Resilience Ratio
Aptevo Therapeutics Inc (APVO) has an Asset Resilience Ratio of 11.65% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2017)
This chart shows how Aptevo Therapeutics Inc's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Aptevo Therapeutics Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Aptevo Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see APVO company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $9.19 Million | 11.65% |
| Total Liquid Assets | $9.19 Million | 11.65% |
Asset Resilience Insights
- Moderate Liquidity: Aptevo Therapeutics Inc has 11.65% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Aptevo Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Aptevo Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Aptevo Therapeutics Inc (2016–2017)
The table below shows the annual Asset Resilience Ratio data for Aptevo Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 62.98% | $73.69 Million | $117.01 Million | +14.15pp |
| 2016-12-31 | 48.82% | $44.85 Million | $91.86 Million | -- |
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune … Read more